CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Triple negative breast cancer (TNBC) represents approximately 15% of all breast cancers (BC) wo ...
Phase 1, Phase 2
Valencia, Comunidad Valenciana, Spain and 23 other locations
This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...
Phase 3
Valencia, Spain and 199 other locations
in patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC), refractory to ...
Phase 2
Valencia, Spain and 9 other locations
the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperable recurrent triple...
Phase 3
Valencia, Spain and 135 other locations
to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received n...
Phase 3
Valencia, Spain and 73 other locations
previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors...
Phase 3
Valencia, Spain and 508 other locations
for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple...
Phase 2
Valencia, Spain and 108 other locations
after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC). The prim...
Phase 2
Valencia, Valenciana, Comunitat, Spain and 121 other locations
with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors...
Phase 3
Valencia, Spain and 508 other locations
vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).After a screening ph...
Phase 3
Valencia, Spain and 192 other locations
Clinical trials
Research sites
Resources
Legal